Cdymax (India) Pharma Private Limited - Company Profile

It is a pharma private limited company based in Bangalore, Karnataka, India, established in 1994.
1994 Bangalore, Karnataka, India Active
Last Updated:
Access Report
About Cdymax (India) Pharma Private Limited

Cdymax (India) Pharma Private Limited, a active private limited company, was established on 27 October 1994 in Bangalore, Karnataka, India. Engaging in api manufacturers within the manufacturing sector, it holds CIN: U85110KA1994PTC016472. Registered under ROC Roc Bangalore. it is unlisted. It has an authorized capital of ₹10.00 Cr and a paid-up capital of ₹8.88 Cr.

Formerly known as Cdymax (India) Pharma Private Limited, Intermed Labs Private Limited. It upholds a compliant status. Employing 493 professional, Its leadership includes Santosh Datta Naik (Director), Manorama Avinash (Director). Past directors included Li Jingpeng, Li Jinliang, Rajeev Venkatesh Jahagirdar. It holds ₹82.98 Cr open charges and ₹66.47 Cr settled loans. Its latest AGM occurred on 29 September 2025, with the balance sheet filed on 31 March 2025. It is based at 116/117 Kiadb Indl Areajigani 2Nd Phase Bangalore, Bangalore, Karnataka, 560105.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U85110KA1994PTC016472

  • Registration Number

    016472

  • Incorporation Date

    27 October 1994

  • Authorized Capital

    ₹10.00 Cr

  • Paid-Up Capital

    ₹8.88 Cr

  • ROC Code

    Roc Bangalore

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 10.00 Cr
  • Paid Up Capital ₹ 8.88 Cr
  • Company Age 31 Year, 4 Months
  • Last Filing with ROC 31 Mar 2025
  • Open Charges ₹ 82.98 Cr
  • Satisfied Charges ₹ 66.47 Cr
  • Revenue Growth **** 2.28%
  • Profit Growth **** -102.95%
  • Ebitda **** -838.58%
  • Net Worth -31.48%
  • Total Assets -16.65%
Company report

Cdymax (India) Pharma Private Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Cdymax (India) Pharma Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Cdymax (India) Pharma Private Limited?
Current Directors
Name Designation Appointment Date Status
Santosh Datta Naik Director 08 Jan 2024 Current
Manorama Avinash Director 07 May 2011 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Director 29 Aug 2011 Past
Pramod Abcsdd Managing Director 29 Aug 2011 Past
Pramod Abcsdd Additional Director 29 Sep 2021 Past
Pramod Abcsdd Additional Director 29 Sep 2024 Past
Pramod Abcsdd Director 01 Jul 2009 Past
Pramod Abcsdd Director 29 Aug 2011 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Cdymax (India) Pharma.

Cdymax (India) Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.28% increase. The company also saw a substantial fall in profitability, with a 102.95% decrease in profit. The company's net worth observed a substantial decline by a decrease of 31.48%.

Cdymax (India) Pharma revenue growth over time
Cdymax (India) Pharma profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 2.28%
*******
*******
*******
*******
Revenue from Operations
*******
 1.15%
*******
*******
*******
*******
Total Assets
*******
 -16.65%
*******
*******
*******
*******
Profit or Loss
*******
 -102.95%
*******
*******
*******
*******
Net Worth
*******
 -31.48%
*******
*******
*******
*******
EBITDA
*******
 -838.58%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Cdymax (India) Pharma?

In 2023, Cdymax (India) Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹829,810,000.00

Satisfied Charges

₹664,738,000.00

Charges Breakdown by Lending Institutions
  • Hdfc Bank Limited : 45.00 Cr
  • Others : 37.98 Cr
Latest Charge Details
Date Lender Amount Status
20 May 2025 Others ₹20.00 Cr Open
30 Nov 2021 Others ₹5.99 Cr Open
20 Aug 2020 Hdfc Bank Limited ₹45.00 Cr Open
03 May 2018 Others ₹6.00 M Open
03 May 2018 Others ₹6.00 M Open

Explore comprehensive loan charge details -

How Many Employees Work at Cdymax (India) Pharma?

Cdymax (India) Pharma has a workforce of 493 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Cdymax (India) Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cdymax (India) Pharma's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Cdymax (India) Pharma
Recent Activity within the Organization
  • Annual General Meeting

    The activity Cdymax (India) Pharma Private Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records. was completed.

  • Charges

    Progress on A charge with Others amounted to Rs. 20.00 Cr with Charge ID 101106111 was registered on 20 May 2025. was documented.

  • Balance Sheet

    The activity Cdymax (India) Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Bangalore. was completed.

  • Charges

    A charge registered on 19 Oct 2017 via Charge ID 100131951 with Others was fully satisfied on 20 Feb 2025. was recorded as a recent event.

  • Charges

    Progress on A charge registered on 13 Jun 2019 via Charge ID 100267725 with Others was fully satisfied on 25 Jun 2024. was documented.

  • Director Appointment

    Santosh Datta Naik was appointed as a Director was appointed as a Director on 08 Jan 2024 & has been associated with this company since 2 years 2 months . was recorded as a recent event.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Cdymax (India) Pharma Private Limited?

The CIN of Cdymax (India) Pharma Private Limited is U85110KA1994PTC016472.

Where is Cdymax (India) Pharma Private Limited headquartered?

Cdymax (India) Pharma Private Limited is headquartered at 116/117 Kiadb Indl Areajigani 2Nd Phase Bangalore, Bangalore, Karnataka, 560105.

When was Cdymax (India) Pharma Private Limited incorporated?

Cdymax (India) Pharma Private Limited was incorporated on 27 October 1994.

Who are the current directors of Cdymax (India) Pharma Private Limited?

The current directors of Cdymax (India) Pharma Private Limited are

What is the primary industry of Cdymax (India) Pharma Private Limited?

The primary industry of Cdymax (India) Pharma Private Limited is Manufacturing.

Is Cdymax (India) Pharma Private Limited a listed company?

Cdymax (India) Pharma Private Limited is unlisted.

What is the capital structure of Cdymax (India) Pharma Private Limited?

The authorized capital of Cdymax (India) Pharma Private Limited is ₹10.00 Cr, and the paid-up capital is ₹8.88 Cr.

What is the compliance status of Cdymax (India) Pharma Private Limited?

The compliance status of Cdymax (India) Pharma Private Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available